Intrinsic Therapeutics Files PMA Application for Barricaid in Lumbar Discectomy

Intrinsic Therapeutics filed a Premarket Approval application with FDA for the Barricaid® Anular Closure device. The submission was based on 2-year outcomes of 554 trial subjects with a high risk of reherniation, subsequent reoperation and rehospitalization.

The Barricaid Anular Closure device is reported to be the first of its kind in a...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us